Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HLA-B27-associated uveitis: overview and current perspectives.

Eric B Suhler1, Tammy M Martin, James T Rosenbaum

  • 1Casey Eye Institute, Oregon Health & Science University, and Portland VA Medical Center, Ophthalmology Service, 97239, USA. eric.suhler@med.va.gov

Current Opinion in Ophthalmology
|November 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis and characterization of soquelitinib a selective ITK inhibitor that modulates tumor immunity.

npj drug discovery·2026
Same author

One-year CALM Outcomes: Data From a Real-world Registry Study of the 0.18-mg Fluocinolone Acetonide Intravitreal Implant for the Treatment of Patients With Non-infectious Uveitis Affecting the Posterior Segment.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized Clinical Trial.

JAMA ophthalmology·2026
Same author

OCT-Based Evaluation of Vitreous Haze in the First-Line Antimetabolites as Steroid-Sparing Treatment Uveitis Trial.

Ophthalmology science·2026
Same author

Interpretable Deep Learning for OCT-Based Diagnosis of Vitreoretinal Lymphoma Versus Uveitis.

Translational vision science & technology·2026
Same author

Cytomegalovirus-associated Panretinal Occlusive Vasculopathy without Retinal Necrosis as the Heralding Feature of Good Syndrome.

Retinal cases & brief reports·2026

Human leukocyte antigen B27 (HLA-B27)-associated uveitis is a common cause of vision loss. Advances in understanding its pathogenesis and genetic links are improving treatment options, including novel therapies.

Area of Science:

  • Ophthalmology
  • Immunology
  • Genetics

Background:

  • HLA-B27-associated uveitis is a leading cause of ocular morbidity in community practice.
  • Understanding its pathogenesis is crucial for managing this common condition.

Purpose of the Study:

  • To review current knowledge on the pathogenesis, clinical presentation, and treatment of HLA-B27-associated uveitis.
  • To highlight recent advances in understanding the genetic basis and therapeutic strategies for this condition.

Main Methods:

  • Literature review of current scientific knowledge.
  • Analysis of advances in understanding disease pathogenesis and genetic underpinnings.
  • Evaluation of emerging and established treatment modalities.

Main Results:

Related Experiment Videos

  • Significant progress has been made in understanding the pathogenesis and genetic factors of HLA-B27-associated ocular and systemic diseases.
  • Alternative therapies, including sulfa antibiotics and tumor necrosis factor-alpha inhibitors, are increasingly important in managing HLA-B27-associated uveitis.

Conclusions:

  • Future research will likely bring further breakthroughs in the genetic epidemiology and treatment of HLA-B27-associated uveitis.
  • Continued investigation into genetic factors and novel therapies promises improved patient outcomes.